Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
MWN-AI** Summary
Ascendis Pharma A/S, a biopharmaceutical company based in Copenhagen, Denmark, has announced its participation in the TD Cowen 46th Annual Health Care Conference on March 2, 2026. Executives from Ascendis Pharma will engage in a virtual fireside chat beginning at 11:10 a.m. Eastern Time. Investors will be able to access a live webcast of the event on the company’s website, with a replay available for 30 days afterward.
Ascendis Pharma is recognized for its innovative TransCon technology platform, aimed at developing therapies that address significant unmet medical needs. The company’s mission is rooted in its core values: Patients, Science, and Passion, driving its commitment to impactful product innovation. In addition to its headquarters in Denmark, Ascendis operates facilities across Europe and the United States, further bolstering its global presence.
The announcement includes forward-looking statements about Ascendis’ future operations and the potential of its TransCon technology. The company reiterated that these statements involve substantial risks and uncertainties, and actual results may differ from projections. Key factors that may impact outcomes include reliance on third-party manufacturers, regulatory review processes, clinical development risks, and market acceptance challenges.
For further insights into these forward-looking statements and risks associated with Ascendis' business, stakeholders are encouraged to review the company’s Annual Report filed with the U.S. Securities and Exchange Commission (SEC). Ascendis emphasizes its commitment to transparency while also protecting its intellectual property and business strategies. As the company continues to advance its portfolio, it remains open to opportunities for licensing, collaborations, and strategic investments. The announcement underscores Ascendis Pharma's proactive communication with investors as it navigates the dynamic landscape of biopharmaceutical development.
MWN-AI** Analysis
As Ascendis Pharma (Nasdaq: ASND) prepares to participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026, investors should approach the stock with both caution and optimism. Ascendis Pharma is showcasing its innovative TransCon technology, which underscores its commitment to addressing unmet medical needs. This platform could potentially position the company favorably in a competitive biopharmaceutical landscape.
Investors should closely monitor the outcomes discussed during the conference, particularly regarding Ascendis' development pipeline and any new data that may emerge about its ongoing clinical studies. Ascendis’ emphasis on best-in-class therapies could indicate strong commercial potential, but it is essential to be aware of the associated risks. Forward-looking statements in the company’s communications highlight uncertainties tied to regulatory approvals, clinical trial results, and potential market acceptance, all of which could significantly impact stock performance.
Further, any insights shared by executives during the event could influence short-term price movements. For instance, news regarding new collaborations or advancements in their trials may attract investor interest, while setbacks could lead to volatility. Given the nature of biopharmaceuticals, it is advisable for potential investors to assess their risk tolerance, especially considering the dependency on third-party partners for manufacturing and distribution.
For those already holding shares, maintaining a diversified portfolio and setting stop-loss orders might be prudent strategies amid the inherent uncertainties associated with biotech investments. As always, investors should remain vigilant about external factors—such as market trends and economic conditions—that could affect Ascendis’ capacity to deliver on its promises, as articulated in their forward-looking statements. In conclusion, while Ascendis Pharma presents a compelling opportunity, thorough due diligence is essential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts.
A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients, and (ii) Ascendis’ ability to apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third?party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on?market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom?to?operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, and TransCon are trademarks owned by the Ascendis Pharma group. © March 2026 Ascendis Pharma A/S.
| Investor Contacts: | Media Contact: |
| Chad Fugere | Melinda Baker |
| Ascendis Pharma | Ascendis Pharma |
| ir@ascendispharma.com | media@ascendispharma.com |
| Patti Bank | |
| ICR Healthcare | |
| +1 (415) 513-1284 | |
| patti.bank@icrhealthcare.com | |
FAQ**
What key insights do you expect Ascendis Pharma A/S (ASND) executives to share during the virtual fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026?
How does Ascendis Pharma A/S (ASND) plan to address potential challenges related to regulatory approval and market acceptance for their therapies?
Can you elaborate on how the TransCon technology platform of Ascendis Pharma A/S (ASND) differentiates its product development approach from competitors in the biopharmaceutical space?
What strategies does Ascendis Pharma A/S (ASND) have in place to mitigate risks associated with manufacturing and supply chain disruptions impacting their future product launches?
**MWN-AI FAQ is based on asking OpenAI questions about Ascendis Pharma A/S (NASDAQ: ASND).
NASDAQ: ASND
ASND Trading
1.29% G/L:
$241.61 Last:
166,300 Volume:
$239.73 Open:
